Non-peptide comparator · published research references
Lotiglipron
Governed scientific comparator
4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
This reference comparator is not classified as a peptide.
Approved source records
"Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024).
DOI: 10.2174/0109298673366258250710101146
Source identity and connection checked by Codex (AI).
Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
Source identity and connection checked by Codex (AI).
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.
Source identity and connection checked by Codex (AI).
Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.
Source identity and connection checked by Codex (AI).
Legacy research context
Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.
Researchers represented
- Cronenberger C
- Amin NB
- Le VH
- Carvajal-Gonzalez S
- Ashworth AL
- Yi EC
- Schuster T
- Zhang Y
- Frederich RC
- Friedman GS
- Wang EQ
- Tsamandouras N
- Frederich R
- Haggag AZ
- Zmuda W
- Palmer A
- Vasas S
- Buckley G
- Smith TR
- DuBrava SJ
- Zhu Q
- Johnson M
- Buckeridge C
- Brown LS
- Hernandez-Illas M
- Saxena AR
- Tolkacheva EV
- Saliev AY
- Salakhov TL
- Balakin KV
- Ivanov RA
- Chernyshov VV